18 research outputs found
Effect of suckler cow vaccination against glycoprotein E (gE)-negative bovine herpesvirus type 1 (BoHV-1) on passive immunity and physiological response to subsequent bovine respiratory disease vaccination of their progeny
peer-reviewedThe study objectives were: 1) to characterise the development of immunocompetence in beef suckler calves from birth to three months of age, and 2) to trace glycoprotein E (gE)-negative bovine herpesvirus type 1 (BoHV-1) antibodies from dam to calf and subsequent vaccination against pneumonia. Thirty multiparous beef suckler, spring-calving cows, consisting of two genotypes were involved; Limousin Ă Friesian (LF) and Charolais Ă Limousin (CL). Cows were immunised against the inactivated antigen strain of BoHV-1 (gE- (IBR marker vaccine) at day â 84 and received a booster at day â 56 relative to the expected calving date (d 0). Calves were immunised at 14 and 42 days of age against PI-3 virus, BRSV and Mannheimia (Pasteurella) haemolytica serotype A1 using a commercial vaccine administered subcutaneously. Additionally, calves were immunised against BoHV-1 at 42 days of age, using 1 dose of a live commercial vaccine administered intranasally. Blood samples were collected from all calves (n = 30) via jugular venipuncture at birth, prior to colostrum feeding (0 h), at 12 h (h), 24 h, 72 h and 168 h after the initial feeding of colostrum, and at d 7, 14, 28, 42, 56 and 84 post birth. The mean ratio of gE negative antibodies circulating in the blood of LF and CL dams pre-partum scored negative to gE ab (S/N â„ 0.70). Antibody levels of BoHV-1 (wild type (wt)) peaked at 12 h post-birth in calves and declined thereafter, as the maternal antibodies decayed. There was no difference in BoHV-1 and BRSV antibody levels in calves post vaccination.This research was funded by the Irish Government under the National Development Plan 2007-2013, Department of Agriculture, Food and the Marine (DAFM) Research Stimulus Fund ((Grant number: 11/S/131) (B. Earley, Principal Investigator)). Katie Tiernan was in receipt of a post-graduate fellowship as part of 11/S/131
A Delphi Study to Identify Research Priorities for the Therapy Professions in Northern Ireland - Executive Summary Report
The Identification of Research Priorities for Therapy Professions in Ireland - Summary Report
Fixed dose rivaroxaban can be used in extremes of bodyweight: a population pharmacokinetic analysis
Experimental challenge with bovine respiratory syncytial virus in dairy calves: bronchial lymph node transcriptome response
Publication history: Accepted - 19 September 2019; Published online - 14 October 2019.Bovine Respiratory Disease (BRD) is the leading cause of mortality in calves. The objective of this study
was to examine the response of the hostâs bronchial lymph node transcriptome to Bovine Respiratory
Syncytial Virus (BRSV) in a controlled viral challenge. Holstein-Friesian calves were either inoculated
with virus (103.5 TCI D50/ml Ă 15 ml) (n = 12) or mock challenged with phosphate buffered saline (n = 6).
Clinical signs were scored daily and blood was collected for haematology counts, until euthanasia at day
7 post-challenge. RNA was extracted and sequenced (75 bp paired-end) from bronchial lymph nodes.
Sequence reads were aligned to the UMD3.1 bovine reference genome and differential gene expression
analysis was performed using EdgeR. There was a clear separation between BRSV challenged and
control calves based on gene expression changes, despite an observed mild clinical manifestation
of the disease. Therefore, measuring host gene expression levels may be beneficial for the diagnosis
of subclinical BRD. There were 934 differentially expressed genes (DEG) (p < 0.05, FDR <0.1, fold
change >2) between the BRSV challenged and control calves. Over-represented gene ontology terms,
pathways and molecular functions, among the DEG, were associated with immune responses. The
top enriched pathways included interferon signaling, granzyme B signaling and pathogen pattern
recognition receptors, which are responsible for the cytotoxic responses necessary to eliminate the
virus.This project was funded by the Irish Department of Agriculture and the Department of Agriculture, Environment
and Rural Affairs, Northern Ireland, as part of the US-Ireland R&D partnership call (RMIS_0033 Project 16/
RD/US-ROI/11). JFT and JWK were supported by Grant Number 2017-67015-26760 from the United States
Department for Agriculture National Institute for Food and Agriculture
Whole blood transcriptome analysis in dairy calves experimentally challenged with Bovine Herpesvirus 1 (BoHV-1) and comparison to a Bovine Respiratory Syncytial Virus (BRSV) challenge
Publication history: Accepted - 25 January 2023; Published online - 17 February 2023Bovine herpesvirus 1 (BoHV-1), is associated with several clinical syndromes in cattle,
among which bovine respiratory disease (BRD) is of particular significance. Despite
the importance of the disease, there is a lack of information on the molecular
response to infection via experimental challenge with BoHV-1. The objective of this
study was to investigate the whole-blood transcriptome of dairy calves
experimentally challenged with BoHV-1. A secondary objective was to compare
the gene expression results between two separate BRD pathogens using data from a
similar challenge study with BRSV. Holstein-Friesian calves (mean age (SD) = 149.2
(23.8) days; mean weight (SD) = 174.6 (21.3) kg) were either administered BoHV-1
inoculate (1 Ă 107
/mL Ă 8.5 mL) (n = 12) or were mock challenged with sterile
phosphate buffered saline (n = 6). Clinical signs were recorded daily from day (d) â1 to
d 6 (post-challenge), and whole blood was collected in Tempus RNA tubes on d six
post-challenge for RNA-sequencing. There were 488 differentially expressed (DE)
genes (p < 0.05, False Discovery rate (FDR) < 0.10, fold change â„2) between the two
treatments. Enriched KEGG pathways (p < 0.05, FDR <0.05); included Influenza A,
Cytokine-cytokine receptor interaction and NOD-like receptor signalling. Significant
gene ontology terms (p < 0.05, FDR <0.05) included defence response to virus and
inflammatory response. Genes that are highly DE in key pathways are potential
therapeutic targets for the treatment of BoHV-1 infection. A comparison to data from
a similar study with BRSV identified both similarities and differences in the immune
response to differing BRD pathogensThis project was funded by the Irish Department of Agriculture, Food and the Marine (DAFM) and the Department of Agriculture, Environment and Rural Affairs (DAERA), Northern Ireland, as part of the US-Ireland R&D partnership call (RMIS_0033 Project 16/RD/US-ROI/11). JT and JK were supported by Grant No. 2017-67015-26760 from the United States Department for Agricultureâs National Institute for Food and Agricultur
Finishing the euchromatic sequence of the human genome
The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers âŒ99% of the euchromatic genome and is accurate to an error rate of âŒ1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead
Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19
IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19.
Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19.
DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 nonâcritically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022).
INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (nâ=â257), ARB (nâ=â248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; nâ=â10), or no RAS inhibitor (control; nâ=â264) for up to 10 days.
MAIN OUTCOMES AND MEASURES The primary outcome was organ supportâfree days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes.
RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ supportâfree days among critically ill patients was 10 (â1 to 16) in the ACE inhibitor group (nâ=â231), 8 (â1 to 17) in the ARB group (nâ=â217), and 12 (0 to 17) in the control group (nâ=â231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ supportâfree days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively).
CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570
Video Conferencing for Special Needs Community
Video Conferencing for Special Needs Community. The overall aim of this project is to establish a model of good practice in utilising the combination of video conferencing and VLE to support an online learning community for special learning needs students. Although this model is for a particular learning group it can be rolled out to all learner groups of all levels within training organisations, FE colleges and universities.
By establishing this model of good practice it will increase efficiency and reduce travel cost, time and carbon foot print for learners and staff.
Workload for infection prevention and control teams in preventing nosocomial tuberculosis: an underestimated burden
Tuberculosis (TB) remains a leading cause of mortality with an estimated 1.5 million deaths globally in 2020.The control and prevention of TB in hospitals is achieved by administrative approaches (early investigations and diagnosis), engineering measures (isolation rooms) and personal respiratory protection. A hospital infection prevention and control (IPC) plan is crucial to ensure prompt detection and isolation of patients with suspected and confirmed TB to prevent cross-infection.</p